The present invention relates to an improved powdered polyvinyl alcohol (PVA), which can be used for pharmaceutical products, and that due to its improved properties can be better dosed during formulation processes. Furthermore, this invention refers to pharmaceutical formulations comprising polyvinyl alcohol as carrier matrix and their use.